NINDS Exploratory Clinical Trials for Small Business (R42)
The summary for the NINDS Exploratory Clinical Trials for Small Business (R42) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
NINDS Exploratory Clinical Trials for Small Business (R42): The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only STTR Phase II and Fast-Track applications are supported under this program. STTR Phase I applications are only accepted as part of a Fast-track application.
Federal Grant Title: | NINDS Exploratory Clinical Trials for Small Business (R42) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-15-278 |
Type of Funding: | Grant |
CFDA Numbers: | 93.853 |
CFDA Descriptions: | Extramural Research Programs in the Neurosciences and Neurological Disorders |
Current Application Deadline: | Apr 5, 2018 |
Original Application Deadline: | Apr 5, 2018 |
Posted Date: | Jun 15, 2015 |
Creation Date: | Jun 15, 2015 |
Archive Date: | May 6, 2018 |
Total Program Funding: | |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following:
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. See full announcement for details. - Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-15-278.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...
- • Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contribution...
- • Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging fin...
- • NINDS Program Project Grant (P01 Clinical Trial Optional)
- • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44)
- • NINDS Institutional Center Core Grants to Support Neuroscience Research
- • Career Development Award to Promote Diversity in Neuroscience Research
- More Grants from the National Institutes of Health
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...